News

Two tumor cells, one with forcefield. two blue spheres with green and purple spheres on them

Kinase Closed: Shutting Down Cancer's Escape Routes

MIT News

March 26, 2026

Forest White and Cameron Flower PhD ’24 have uncovered why drugs that inhibit tyrosine kinase signaling pathways, such as imatinib (Gleevec), fail in some patients.  By analyzing tumor phosphoproteomics, the White Lab team found that many resistant cells are intrinsically wired to resist tyrosine kinase inhibitors: backup signaling networks are already running to support vital functions such as cell growth and division, even when tyrosine kinase inhibitors work as intended. 

As reported in Proceedings of the National Academy of Sciences, researchers overcame this resistance in cell models by pairing a tyrosine kinase inhibitor with a drug that targets the backup pathway—an approach currently in clinical trials for lung cancer. 

“We are really excited to watch these clinical trials and to see how well patients do on these combinations. And I really think there’s a future for using tyrosine phosphoproteomics to guide this clinical decision-making,” White says. The research was funded in part by the MIT Center for Precision Cancer Medicine.
 

Filter by

Filter by Title/Description

Filter by Topic

Filter by Year

Showing 11–20 of 718 stories

Spiky Success

Nature Biomedical Engineering

March 2, 2026

Immune monitoring in cancer, vaccination, infection, and autoimmune disorders requires detection of certain antigen-specific immune cells, yet because they are few and far between in the blood stream, finding them is a challenge.A platform from the Hammond and Irvine labs cleverly exploits memory T cells to induce circulating immune cells of interest to accumulate in the skin, which can then be sampled non-invasively by a microneedle patch. Recently published in Nature Biomedical Engineering, earlier work on this approach was supported by the Bridge Project and appears in the KI Image Awards Archive. 
 

Decoding Cancer Evolution 

MIT News

February 20, 2026

“We aim to decode cancer evolution and therapy resistance,” says MIT Biology’s new Assistant Professor Matthew G. Jones in a “3 Questions” Q&A. His lab combines AI, single‑cell lineage tracing, and predictive models to anticipate tumor progression, identify vulnerabilities, and guide strategies for more effective cancer treatment. 

From The Curiosity Desk

WGBH

February 19, 2026

On GBH’s The Curiosity Desk, Angela Belcher and Sangeeta Bhatia talk nanomaterial properties, light wavelengths, and ovarian cancer. Working toward better patient outcomes, they highlight the “huge window of opportunity” before precancerous lesions leave the fallopian tube and discuss their work on early detection and intervention. 

Love Lab improves drug production with AI

MIT News

February 16, 2026

In a study published in Proceedings of the National Academy of Sciences, the Love Lab designed an AI model for more efficient yeast-based production of protein drugs for the treatment of cancer and other diseases.Led by former postdoc and Mazumdar-Shaw International Oncology Fellow Harini Narayanan, the researchers used the Love Lab's yeast-based biomanufacturing platform to develop a large language model that optimizes genetic sequences for protein production—an unpredictable part of advancing new biologic drugs to the clinic.The study reflects Love's longstanding interest in improving both small- and industry-scale drug manufacturing processes. His perspectives as co-director of the new MIT Initiative for New Manufacturing are featured in the MIT Technology Review.

Irvine Lands on TIME100 Health 2026 List

Time Magazine

February 12, 2026

Long-time faculty member Darrell Irvine has been named to the 2026 TIME100 Health, an annual list of the 100 individuals who most influenced global health this year. Irvine is recognized for his work empowering the immune system to fight cancer, HIV, and other diseases, including therapeutic cancer vaccine approaches developed in his KI lab that have shown stunning promise in trials headed by KI startup Elicio Therapeutics. 

Sasisekharan elected to the National Academy of Engineering

MIT News

February 10, 2026

Congratulations to Ram Sasisekharan on his 2026 election to the National Academy of Engineering—one of the highest professional distinctions that can be accorded to an engineer. Sasisekharan was recognized for his groundbreaking contributions to public health and biomedical engineering, including discovering the U.S. heparin contaminant in 2008 and creating clinical antibodies for Zika, dengue, SARS-CoV-2, and other diseases.  
 

Vander Heiden and Shaw Elected as AACR Fellows

American Association for Cancer Research

February 4, 2026

KI Director Matthew Vander Heiden has been elected to the 2026 class of Fellows of the AACR Academy. Membership honors scientists whose work has had a lasting global impact on cancer research, including Vander Heiden’s work in cancer metabolism.  Alice Shaw, MD, PhD, was also elected, for her work in targeted therapies and precision oncology. A Jacks Lab alumna, she also served as the Koch Institute's inaugural Charles W. (1955) and Jennifer C. Johnson Clinical Investigator.  

Ultrasound Goes Ultra Accessible 

MIT News

February 2, 2026

A portable, smartphone-sized 3D ultrasound sensor developed in the lab of KI alum Canan Dagdeviren could improve early breast cancer detection for high‑risk individuals. Clinical trials are evaluating its ability to detect tumors earlier than yearly mammograms in high-risk patients, and MIT entrepreneurship programs are helping a startup advance commercialization of this low-cost, miniaturized technology.

Gensaic on target: AI-powered delivery for smarter medicine

MIT News

January 30, 2026

Building on insights from her work as a graduate student adapting the Belcher Lab’s signature bacteriophage delivery platform, alum Uganda Tsedev has co‑launched Gensaic. The company’s AI‑powered platform helps guide design of precision protein “shuttles” that deliver therapeutic molecules to target tissues. This tissue‑selective approach could transform treatments for metabolic and other diseases while reducing side effects.

Crystal Blue Sensation

Science Translational Medicine

January 28, 2026

By developing slow release, crystal forms of drugs that block the CSF1R immune pathway and encapsulating them with insulin producing cells in alginate spheres, the Anderson/Langer group can reduce immune reactions that lead to biomedical implant failure and ensure stable, long-term glycemic control in models of diabetes. Early versions of this technology appear in the KI Image Awards Archive; a recent Science Translational Medicine study highlights contexts where the approach could be successful.